SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Botker H E)
 

Sökning: WFRF:(Botker H E) > The Effect of Evero...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003481naa a2200469 4500
001oai:lup.lub.lu.se:561cc7ce-1509-451a-925c-967b5ec7b7ba
003SwePub
008160401s2015 | |||||||||||000 ||eng|
024a https://lup.lub.lu.se/record/75967122 URI
024a https://doi.org/10.1111/ajt.132142 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Arora, S.4 aut
2451 0a The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial
264 1b Elsevier BV,c 2015
520 a Early initiation of everolimus with calcineurin inhibitor therapy has been shown to reduce the progression of cardiac allograft vasculopathy (CAV) in de novo heart transplant recipients. The effect of de novo everolimus therapy and early total elimination of calcineurin inhibitor therapy has, however, not been investigated and is relevant given the morbidity and lack of efficacy of current protocols in preventing CAV. This 12-month multicenter Scandinavian trial randomized 115 de novo heart transplant recipients to everolimus with complete calcineurin inhibitor elimination 7-11 weeks after HTx or standard cyclosporine immunosuppression. Ninety-five (83%) patients had matched intravascular ultrasound examinations at baseline and 12 months. Mean (SD) recipient age was 49.9 +/- 13.1 years. The everolimus group (n=47) demonstrated significantly reduced CAV progression as compared to the calcineurin inhibitor group (n=48) (Maximal Intimal Thickness 0.03 +/- 0.06 and 0.08 +/- 0.12mm, Percent Atheroma Volume 1.3 +/- 2.3 and 4.2 +/- 5.0%, Total Atheroma Volume 1.1 +/- 19.2mm(3) and 13.8 +/- 28.0mm(3) [all p-values0.01]). Everolimus patients also had a significantly greater decline in levels of soluble tumor necrosis factor receptor-1 as compared to the calcineurin inhibitor group (p=0.02). These preliminary results suggest that an everolimus-based CNI-free can potentially be considered in suitable de novo HTx recipients.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
700a Andreassen, A. K.4 aut
700a Andersson, B.4 aut
700a Gustafsson, F.4 aut
700a Eiskjaer, H.4 aut
700a Botker, H. E.4 aut
700a Rådegran, Göranu Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-grd
700a Gude, E.4 aut
700a Ioanes, D.4 aut
700a Solbu, D.4 aut
700a Sigurdardottir, V.4 aut
700a Dellgren, G.4 aut
700a Erikstad, I.4 aut
700a Solberg, O. G.4 aut
700a Ueland, T.4 aut
700a Aukrust, P.4 aut
700a Gullestad, L.4 aut
710a Kardiologib Sektion II4 org
773t American Journal of Transplantationd : Elsevier BVg 15:7, s. 1967-1975q 15:7<1967-1975x 1600-6135
856u http://dx.doi.org/10.1111/ajt.13214y FULLTEXT
8564 8u https://lup.lub.lu.se/record/7596712
8564 8u https://doi.org/10.1111/ajt.13214

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy